Hubei Biocause Pharmaceutical (000627.SZ) subsidiary CHINA BEST life insurance company's accumulated premium income from January to August reached approximately 29.03 billion yuan.

17/09/2024

Tianmao Group (000627.SZ) has announced that its subsidiary, Guohua Life Insurance Co., Ltd., a company controlled by the company, will follow according to...

Hubei Biocause Pharmaceutical (000627.SZ) announces that its controlling subsidiary, CHINA BEST Life Insurance Co., Ltd., is proceeding with business development in accordance with the overall strategy of "firmly transitioning for development, highlighting value growth, comprehensively improving capabilities, and moving towards a mature insurance enterprise". The company is focusing on value-based business, continuously promoting business structure optimization. From January 1, 2024 to August 31, 2024, the accumulated original insurance premium income is approximately 29.03 billion yuan.

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.